Function, pharmacological correction and maturation of new Indian CFTR gene mutations  by Sharma, Himanshu et al.
Original Articlewww.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 14 (2015) 34–41Function, pharmacological correction and maturation of new
Indian CFTR gene mutationsHimanshu Sharma a,b,1, Mathilde Jollivet Souchet a,1, Isabelle Callebaut c,
Rajendra Prasad b,⁎, Frédéric Becq a,⁎⁎
a Laboratoire Signalisation et Transports Ioniques Membranaires, Université de Poitiers, CNRS, Poitiers, France
b Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh160012, India
c Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), Sorbonne Universités — UPMC Université Paris 06, UMR CNRS 7590,
Muséum National d'Histoire Naturelle, IRD UMR 206, 4 Place Jussieu, Paris, France
Received 11 April 2014; revised 6 June 2014; accepted 11 June 2014
Available online 16 July 2014Abstract
Background: Cystic ﬁbrosis (CF) is rare in India. Most CF mutations identiﬁed are not yet functionally characterized. Hence, genetic counseling
and adoption of therapeutic approach are particularly difﬁcult. Our aim was to study the function and maturation of a spectrum of eleven Indian
CFTR mutations from classical CF and infertile male patients with CBAVD.
Methods: We used Western blot, pharmacology and iodide efﬂux to study CFTR maturation and chloride transport in BHK cells expressing
pEGFP-CFTR constructs for L69H, F87I, S118P, G126S, H139Q, F157C, F494L, E543A, S549N, Y852F and D1270E.
Results: Among these CFTR mutants, only L69H is not processed as a c-band and not functional at 37 °C. However, the functions of L69H and
S549N and the maturation of L69H are corrected at 27 °C and by the investigational drug VX809.
Conclusion: These data should help in developing counseling and therapeutic approaches in India. We identiﬁed L69H as a novel class II CF
mutation.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Missense CF mutations; India; L69H-CFTR; S549N-CFTR; Low temperature; VX8091. Introduction
Cystic fibrosis (CF, MIM #219700), a severe autosomal
recessive disorder of chloride (Cl−) conductance across epithelialAbbreviations: CBAVD, congenital bilateral absence of the vas deferens;
CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance
regulator; GFP, green fluorescent protein; WT-CFTR, wild-type CFTR.
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Acells is caused by mutations in the cystic fibrosis transmembrane
conductance regulator gene (CFTR or ABC C7; MIM # 602421),
which are involved in a wide spectrum of clinical phenotypes
including respiratory distress, chronic pancreatitis and male
infertility due to congenital bilateral absence the vas deferens
(CBAVD, MIM# 22180) [1,2]. To date N1900 mutations have
been identified in the human CFTR gene (http://www.genet.
sickkids.on.ca/home.html). They are progressively subdivided
into six classes based on the mechanism of the disruption of
CFTR [3,4] and the absence of the CFTR protein at the apical
plasma membrane, which include I) defective protein synthesis,
II) impaired protein maturation leading to protein degradation,
III) defective regulation of CFTR channel activity, IV) altered ionic
selectivity and conductance, V) lowered CFTR mRNA amount
and VI) decreased protein stability.ll rights reserved.
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better documented [5–9] due to recent investigations establish-
ing a spectrum of mutations in Indian CF patients [7–9].
F508del was found to be the most common mutation in Indian
CF population with a frequency of 27% [7], which was muchFig. 1. Prevalence of CF in the different regions of India. Map of India representing
basis of elevated sweat chloride, mutation detection or both. Maximum number of
studied here were identified in the northern part of India.less than that of European descent [1]. The striking character-
istics were the presence of severe rare mutations but the
absence of most common mutations identified in the Mediter-
ranean and European populations, clearly indicatesthe hetero-
geneous spectrum of CFTR mutations in the Indian population.the number of CF cases reported from different states of India diagnosed on the
cases was identified from the northern part of India. The 11 CFTR mutations
Fig. 2. Effect of CFTR mutations on the protein maturation. Western blot
experiments using antibodies directed against either the CFTR protein (A and
B) or the GFP tag (C–E). Bands B and C are indicated by arrows. The 11 CFTR
mutations plus WT-CFTR and F508del-CFTR are indicated for each lane.
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called orphan mutation because of their very low incidence.
However, rare familial mutations cannot provide sufficient
information on the phenotype induced by these mutations
(Table 1).
Because the cellular and functional data on these mutations
can improve CF genetic counseling, we examined here the
functional and cellular consequences of eleven rare missense
mutations, L69H, F87I, S118P, G126S, H139Q, F157C,
F494L, E543A, S549N, Y852F and D1270E present in CFTR
gene from both classical CF patients and CBAVD patients,
which have been detected during molecular diagnosis of
Indian CF patients (Fig. 1). CFTR maturation process and the
corresponding ion transport activity were studied by Western
blot analysis and automated iodide efflux assay respectively.
2. Results
2.1. Expression analysis of eleven CFTR mutants
Western blot experiments were performed using antibodies
directed against either the CFTR protein (Fig. 2A and B) or the
GFP tag (Fig. 2C–E) with transfected BHK-21 cells,
WT-CFTR and F508del-CFTR. Except for L69H and
F508del, the profiles of core-glycosylated and mature glyco-
sylated forms were similar to that of WT-CFTR protein. Mature
glycosylated c-band was absent in L69H mutant expressing
cells.
2.2. Functional analysis of the eleven CFTR mutants
The Cl−channel function of CFTR was measured by iodide
efflux for each mutant compared to WT-CFTR. Stimulation of
CFTR ion transport was obtained by forskolin (10 μM) plus
genistein (30 μM) (hereafter noted F + G). We used three
controls: WT-CFTR to measure the maximum response to
F + G; F508del-CFTR and non-transfected cells (noted NT) to
measure the lack of response to these agonists (Fig. 3A). The
activation of nine CFTR mutants F87I, S118P, G126S, H139Q,Table 1
CFTR mutations identified and characterized in Indian CF patients.
Mutation Nucleotide change Location in CFTR Patien
L69H T to A at 338 N-terminal Patien
chlorid
Patien
F87I T to A at 391 MSD1 CBAV
S118P T to C at 484 MSD1 CBAV
G126S G to A at 508 MSD1 CBAV
H139Q C to G at 549 MSD1 CBAV
F157C T to G at 602 MSD1 CBAV
F494L T to C at 1612 NBD1 CBAV
E543A A to C at 1760 NBD1 CBAV
S549N G to A at 1778 NBD1 Patien
Patien
Y852F A to T at 2687 Cytoplasmic region between
regulatory domain and MSD2
CBAV
D1270E T to A at 3942 NBD2 CBAV
MSD: membrane spanning domain, NBD: nucleotide binding domain, CBAVD: coF157C, F494L, E543A, Y852F and D1270E was not
significantly different from WT-CFTR (Fig. 3A for example
of traces and Fig. 3B for a summary). The response to agonists
of S549N-CFTR mutant was reduced (Fig. 3A) compared to
WT-CFTR (Fig. 3B). The most dramatic effect was observed
with the L69H-CFTR mutant, whose response to F + G was
null (Fig. 3A) and not significantly different from F508del-
CFTR (Fig. 3B). This result is in agreement with the Western
blot data showing lack of mature fully glycosylated c-band for
L69H- and F508del-CFTR proteins.t phenotype CFTR dysfunction
t 1: Pancreatic insufficient, sweat
e N 60 mEq/L, S. aureus positive;
t 2: CBAVD
Defective CFTR maturation and
channel activity, class-II CF mutation
D No dysfunction
D No dysfunction
D No dysfunction
D No dysfunction
D No dysfunction
D No dysfunction
D No dysfunction
t 1: Frequent respiratory infection.
t 2: CBAVD
Defective channel activity,
class III mutation
D No dysfunction
D No dysfunction
ngenital bilateral absence of the vas deferens.
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Fig. 3. Functional analysis of the eleven CF mutations. Iodide efflux experiments in transfected BHK-21 cells, WT-CFTR, L69H, F87I, S118P, G126S, H139Q,
F157C, F494L, E543A, S549N, Y852F and D1270E. A. Example of traces for all CFTR mutants as indicated on each graph. The bar above indicates the addition of
forskolin (10 μM) and genistein (30 μM). NT: non-transfected cells. B. Histogram summarizing the data normalized to the efflux of WT-CFTR. N = 4 to 8 for each
condition.
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CFTR mutants
F508del protein is temperature sensitive, that is the
mutant can be rescued from its abnormal ER location to
the plasma membrane by lowering the temperature of the
cells from 37 °C to 27 °C [10]. We studied the effect of
low-temperature with cells expressing L69H and S549N
compared to F508del-CFTR. After 24 h at 27 °C, these cells
were challenged with F + G and the iodide efflux measured.
Compared to cells maintained at 37 °C, the three CFTR
mutants at 27 °C showed augmented responses to F + G
(Fig. 4A). Immunoblots confirmed for L69H that at 27 °C the
proteins acquired a mature state as c-band can be detected
(Fig. 4C, lane 6) but not at 37 °C (Fig. 4C, lane 4). Similar
results were obtained with F508del-CFTR at 27 °C (Fig. 4D,
lane 4) versus 37 °C (Fig. 4D, lane 2).2.4. Rescue by the investigational drug VX809 of L69H and
F508del
The pharmacological corrector VX809 [11] was evaluated on
L69H and compared to F508del. The activation of L69H and
F508del were both significantly corrected when cells were treated
with VX809 (24 h, 10 μM, Fig. 4B).We also performedWestern
blot with L69H and F508del in the presence of VX809 but not
with S549N because it is already mature (Fig. 2A). Remarkably
we detected mature c-band for L69H (Fig. 4C, lane 6) as with the
low-temperature protocol. Again, this is similar to what we
observed for F508del (Fig. 4C, lane 3).
3. Discussion
The present study investigated the potential deleterious
functional consequence of novel rare missense mutations
Fig. 4. Functional rescue of L69H, F508del and S549N by low temperature and VX809. A. Iodide efflux experiments with BHK-21 cells transfected with L69H,
S549N and F508del-CFTR as indicated. Cells were incubated either at 37 °C or 24 h at 27 °C. B. Iodide efflux experiments with cells incubated or not 24 h with
10 μM VX809 at 37 °C as indicated. N = 4 to 8 for each condition. C. Western blot experiments using antibodies directed against the CFTR protein. Each
experimental condition is indicated on each lane with WT-CFTR (lane 1), F508del (lane 2), F508del + VX809 (lane 3), L69H (lane 4), L69H + VX809 (lane 5) and
L69H at 27 °C (lane 6). D. Another immunoblot using anti-CFTR antibodies. Each experimental condition is indicated on each lane with WT-CFTR (lane 1), F508del
(lane 2), F508del + VX809 (lane 3), F508del at 27 °C (lane 4). Bands B and C are indicated by arrows. E. Global view (a) of the model of the 3D structure of human
CFTR (open channel), based on the experimental 3D structure of Sav1866, in an outward-facing conformation according to Mornon et al.[15], on which the mutation
L69H is located (yellow square) MSD1 and 2 are membrane-spanning domains 1 and 2 (in blue and red, respectively). NBD1 and 2 are nucleotide-binding domains 1
and 2 (in light blue and orange, respectively) with ATP molecules bound at the interface (b) Focus on amino acid L69 located in a alpha-helix (purple ribbon)
belonging to the N-terminal extension of CFTR. TM3 and TM6 in blue are the third and sixth transmembrane helices within MSD1, respectively.
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CF/infertility due to CBAVD or both. The collected data include
information on the function and maturation of the mutant
proteins. Additionally, the effects of low temperature and of the
CFTR corrector VX809 were also examined. In our study, the
eleven CFTR mutants i.e. L69H, F87I, S118P, G126S, H139Q,
F157C, F494L, E543A, S549N, Y852F and D1270E produced
different results. The first salient result is the fact that we
identified L69H as a novel class II CF mutation. The trafficking
to the plasma membrane of L69H-CFTR is abnormal as
corroborated by our Western blot analysis, which revealed only
the presence of b-band. Further confocal microscopy imaging
showed the abundance of L69H mutated CFTR proteins in the
ER and absence on the plasma membrane (data not shown).
Therefore, the processing pathway of this variant is similar to that
of F508del-CFTR mutation which is the most common mutation
worldwide. Misfolded F508del-CFTR is retained by the ER and
undergoes ubiquitination, thereby accelerating its proteasome
degradation and reducing F508del-CFTR trafficking to the
plasma membrane [12,13]. To overcome this type of class II
defect, various CF correctors are in the pipeline for pharmaco-
logical developments [11,14]. One of them, VX809, has been
shown to partially restore the abnormal localization of F508del in
epithelial cells [11]. Our results clearly indicated that the L69H
mutant is responsive to VX809 as well as to rescue following low
temperature incubation of cells. These two properties are also
shared by the F508del-CFTR. We propose thus to categorize
L69H as a class II form of CF mutation.
Interestingly, using the structural information provided by
the model of the 3D structure of CFTR, based on the Sav1866
experimental 3D structure [15] (Fig. 4Ea), we evaluated the
possible impact of L69H on CFTR (Fig. 4Eb). L69 is situated
in a short cytosolic α-helix in the N-terminus of CFTR,
preceding the first transmembrane helix TM1 of MSD1. This
helix is also called “elbow helix” and is a conserved feature
among the ABC exporter family. L69 makes part of the
hydrophobic face of this helix, and is in close contact with
hydrophobic side chains of the cytosolic extensions of MSD1
TM helices, located just below the membrane plane (F191 just
before TM3 and especially I368 just after TM6). The network
formed by these hydrophobic amino acids in the cytosolic
N-terminal extension (L69), in the intracellular loop ICL1
(F191) and in the MSD1–NBD1 linker (I368) might thus play
an important role for MSD1 folding and stabilization of this
domain at the membrane and, accordingly, the L69H may
perturb these mechanisms. Supporting this hypothesis is the
fact that VX-809 has been shown to act on MSD1 folding and
that it also rescues functional defects in CFTR caused by
disease-related mutations in the vicinity of the three amino
acids highlighted here (P67L, L206W) [16].
Another important result concerns the S549, located in the
LSGGQ signature motif of NBD1 and may alter the hydrolysis of
ATP to regulate channel activity [1]. S549N causes reduction in
Cl− channel activity classifying it as a class III CF mutation [17].
Normal maturation of S549N-CFTR protein was observed in our
Western blot analysis as reported by others [17]. It is noteworthy
here that S549N defective channel activity was neverthelesspotentiated after incubating cells at 27 °C or VX809, a result
which on the contrary was not anticipated.
The functional characterization of nine other novel muta-
tions associated with CBAVD viz., F87I, S118P, G126S,
H139Q, F157C, F494L, E543A, Y852F and D1270E revealed
that these mutants did not cause any effect on normal CFTR
maturation process and Cl−channel activity. Thus, mutations
with functional consequences were found only in CF patients;
none of those found only in CBAVD patients showed
functional or maturation alteration. Notably, a high frequency
of compound heterozygosis has been reported with severe/mild
or mild/mild mutations in CBAVD patients [18]. Further
research is warranted to explore the secondary genetic factors,
which are responsible for the genesis of vas deferens along with
CFTR mutations.
Our observation supports a rationale for assessing the effects
of VX809 on these rare disease mutations. However, a major
concern in the CF disease is whether pharmacological agents
[14] (correctors) that directly target and restore the loss in
CFTR mediated chloride secretion would be sufficient to slow
or cease the deleterious cascade of events that leads to disease
progression in CF patients.
4. Methods
4.1. Patients profile
Eleven rare missense mutations i.e. L69H, F87I, S118P,
G126S, H139Q, F157C, F494L, E543A, S549N, Y852F, and
D1270E were characterized by using single stranded confor-
mation polymorphism and subsequently by DNA sequencing in
Indian infertile CBAVD male patients [7,8]. The diagnosis of
CBAVD was based on physical examination when both of the
vas deferentia were non-palpable in the scrotal portion, other
component of infertility such as semen analysis (including
volume, pH, sperm count), transrectal ultrasonography, testic-
ular fine needle aspiration cytology (FNAC) for studying the
pattern of spermatogenesis were also evaluated to confirm the
CBAVD diagnosis. All the detected mutations except S549N
are novel, rare mutations identified only from the Indian
population, however, the exact frequency is still not known
[7,8]. Additionally L69H and S549N mutations were also
observed in Indian patients diagnosed with classical CF [7].
The L69H missense mutation was identified in three-month-old
child having classical phenotype like elevated level of sweat
chloride and lung Staphylococcus aureus infection with
respiratory distress. The second adult bearing same mutation
was adult infertile male due to CBAVD along with an elevated
level of sweat chloride but no other sign symptoms of classical
CF. Moreover S549N missense mutation was also observed in
two patients. The first had symptoms of classical CF with
frequent respiratory infection and elevated sweat chloride. The
second was an infertile adult male patient with CBAVD with no
other sign and symptoms of CF. The remaining all nine
mutations viz., G126S, Y852F, F87I, S118P, H139Q, F157C,
F494L, E543A, and D1270E were identified in Indian infertile
males diagnosed with only CBAVD. All the eleven mutations
40 H. Sharma et al. / Journal of Cystic Fibrosis 14 (2015) 34–41were identified in heterozygous states; CFTR mutation in the
second allele could not be detected in any of these patients.
4.2. Cell culture, construction of CFTR mutants and transfection
BHK-21 cells were cultured at 37 °C in 5% CO2 in
Dulbecco's modified Eagle's medium/F-12 + GlutaMAX
(Life Technologies, UK) with 5% fetal calf serum (Lonza,
Belgium), 1% penicillin/streptomycin (Sigma, USA). For
experiments using the low-temperature protocol, cells were
transferred to a cell incubator set at 27 °C for 24 h prior to
further analysis. CFTR mutations were generated by oligonu-
cleotide directed mutagenesis using QuikChange II XL, site
directed mutagenesis kit (Stratagene, La Jolla CA) into the
pEGFP CFTR wt plasmid as described previously [19,20].
4.3. Immunoblot analysis
BHK-21 cells after 48 h of transfection were mixed with
lysis buffer (25 mM Tris–HCl buffer, pH 7.4, 150 mM NaCl,
1% Triton X-100 (Sigma)) containing a cocktail of protease
inhibitors (1X, Roche, USA). Total proteins extracted from
cell lysates were quantified using Bio-Rad protein assay dye
reagent concentrate (Bio-Rad, France). Cell lysate proteins,
50 or 100 μg, were resolved on a 5% polyacrylamide gel
and transferred from the polyacrylamide gel to a PVDF or
nitrocellulose membrane using Bio-Rad electroblotting appa-
ratus. The blot was incubated in TBS, 0.1% Tween 20 (Sigma,
USA) with 1 μg/mL of primary antibody anti-CFTR monoclo-
nal antibody (clone MAB3480; Chemicon International,
Millipore Biosciences Research Reagent, CA) overnight at
4 °C or with a primary antibody anti-green fluorescent protein
(GFP), rabbit polyclonal serum, 1:1000, 5% of milk powder
(Invitrogen, USA) for 1 h at 4 °C. Blot was then incubated in
TBS, 0.1% Tween 20, 5% of milk powder (Sigma, USA) with a
secondary antibody for 1 h at 4 °C. We used anti-mouse IgG,
horseradish peroxidase-linked whole antibody from sheep
(1:10,000) (Amersham, GE Healthcare, UK) for CFTR and
anti-rabbit IgG, horseradish peroxidase-linked whole antibody
from donkey (1:10,000) (Amersham, GE Healthcare, UK) for
anti-GFP. The blot was revealed over an X-ray film with ECL
Western-blotting reagent (Millipore).
4.4. Iodide efflux measurement
CFTR chloride channel activity was assayed by measuring
the rate 125I efflux from cells as previously described [20].
Iodide efflux curves were constructed by a plotting rate of 125I
versus time. All comparisons were based on maximal values for
time-dependent rates (k = peak rates, min−1) excluding the
points used to establish the baseline (k peak − k basal, min−1).
4.5. Statistics
The results are as means ± standard error of the mean
(SEM) of n observations. All statistical tests were performed
using GraphPad Prism version 5.0 for Windows (GraphPadSoftware, San Diego, CA, USA). Datasets were compared
using Student's t-tests. Differences were considered statistically
significant at P b 0.05. ns, no significant difference; *P b 0.05;
**P b 0.01; and ***P b 0.001.
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